Approximately 700,000 people worldwide, die every year from complications of hepatitis C (HCV virus). In 2017, the World Health Organization proposed a plan to eliminate HCV as a public health emergency by 2030. This is possible thanks to new direct-acting antiviral drugs (DAAs), which are innovative medicines that allows for cure rates exceeding 90% and with fewer side effects than older HCV treatments.
However, the price of these drugs is prohibitive in many countries, requiring creative strategies to guarantee adequate access. Brazil is at the forefront of responding to the hepatitis epidemic.